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DiabetesWe report the discovery of the glucose-dependent insulin secretogogue activity of a novel class of
polycyclic guanidines through phenotypic screening as part of the Lilly Open Innovation Drug Discovery
platform. Three compounds from the University of California, Irvine, 1–3, having the 3-arylhexahydropyr-
rolo[1,2-c]pyrimidin-1-amine scaffold acted as insulin secretagogues under high, but not low, glucose
conditions. Exploration of the structure–activity relationship around the scaffold demonstrated the key
role of the guanidine moiety, as well as the importance of two lipophilic regions, and led to the identiﬁ-
cation of 9h, which stimulated insulin secretion in isolated rat pancreatic islets in a glucose-dependent
manner.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.There are greater than 350-million people living with diabetes
mellitus worldwide.1 The majority of diabetes mellitus patients
incur type 2 diabetes, the adult onset variant of the disease,
characterized by elevated blood glucose levels in the settings of
elevated peripheral insulin resistance and impaired insulin
secretion from pancreatic b cells. Several classes of medications
are used to control blood glucose in type 2 diabetes patients,
including insulinotropic agents such as sulfonylureas, DPP-IV
inhibitors and GLP-1 analogues. The use of currently available ther-
apies is tempered by their undesired side effects, increased risk of
hypoglycemia and short durability. The identiﬁcation of small-
molecule insulin secretion agents that operate selectively under
high-glucose conditions and amplify glucose-induced insulin
secretion by novel mechanisms therefore constitutes an opportu-
nity for improvement in the current standard of care for type-2
diabetes.
We previously described a medium-throughput insulin secre-
tion assay that utilized INS-1E insulinoma cells to measure insulin
secretion under conditions of both high (5 mM) and low (0.1 mM)
glucose concentrations.2 Through the Lilly Open Innovation Drug
Discovery platform,3 University of California, Irvine (UCI) com-pounds were submitted in a structurally blinded fashion for phe-
notypic screening, including in the insulin secretion assay. Three
UCI compounds, 1–3, representing the 3-arylhexahydropyrrol-
o[1,2-c]pyrimidin-1-amine scaffold acted as insulin secretagogues
under high glucose conditions (Table 1).4 Compound-stimulated
insulin secretion could not be detected at basal glucose concentra-
tion, suggesting a glucose dependency of their insulinotropic activ-
ity. In comparison, the sulfonylurea glibenclamide is a more potent
insulin secretogogue than the UCI compounds in this assay, but
also stimulates insulin secretion at low glucose concentrations as
shown in Table 1. The observed insulin secretion at low glucose
concentrations is in line with the known propensity for glibencla-
mide to stimulate insulin secretion in vivo in a glucose-indepen-
dent fashion.5,6
As compound 3 stimulated insulin secretion at high glucose in
isolated rat pancreatic islets (data not shown), it was decided to
explore the SAR of this scaffold in an effort to improve potency
and to conﬁrm glucose dependency. We report herein the synthe-
sis and evaluation of 3-arylhexahydropyrrolo[1,2-c]pyrimidin-1-
amines as potential glucose-dependent insulin secretagogues.
Bicyclic guanidines 1–3 could be prepared in six linear-steps by
the route disclosed previously by Overman and Wolfe (Scheme 1).7
Beginning with hydrocinnamaldehyde, Grignard reaction with
3-(ethylenedioxy)propylmagnesium chloride and Mitsunobu
installation of the azide unit gave 4 in good yield.8 Reduction of
the azide with LiAlH4 provided amine 5 in quantitative yield, which
Table 1
Phenotypic screening results identifying 3-arylhexahydropyrrolopyrimidin-1-amine lead compounds 1–3 as glucose dependent secretagogues in comparison with glibenclamide
standarda
5.0 mM Glu 0.10 mM Glu
EC50
(lM)
SEM
(lM)
% Stimulation SEM
(%)
EC50
(lM)
SEM
(lM)
% Stimulation SEM
(%)
Glibenclamide 0.003 0.0002 50 0.1 0.007 0.0002 17 1
1.45 0.25 21 3 >33b
1.25 0.69 34 5 >33b
1.30 0.11 27 7 >33b
a Compounds were tested for insulin secretagogue activity at 5 and 0.1 mM glucose in INS1-E cells (as described in footnote 4). Data were ﬁt to pharmacological models and
mean and error values for potency and efﬁcacy (% stimulation) were calculated.
b No increase in insulin secretion was detected at compound concentrations up to 33 lM.
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Scheme 1. Initial route to bicyclic guanidines illustrated by the synthesis of 2.
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ama’s salt to obtain alkylguanidine acetal 6. Cleavage of protecting
groups and subsequent cyclization upon exposure to TFA at room
temperature, followed by quenching with thiophenol and a salt
switch with dilute aqueous HCl, provided pyrrolidine N,S-
thioaminal hydrochloride salt 7 in 40% yield over three steps.
Copper-mediated cyclocondensation of 7 with the appropriate
alkenes afforded the desired bicyclic guanidines as mixtures of
C3–epimers; this step is exempliﬁed in Scheme 1 by the synthesis
of 2. In this and other similar constructions, the C3 substituent of
the major epimer is equatorial, as readily determined by 1H NMR
analysis.7
An abbreviated, more scalable route to bicyclic guanidines such
as 2 was also utilized (Scheme 2). In this sequence, Mitsunobudisplacement of secondary alcohol 8 with commercially available
di-(Boc)guanidine provided intermediate 6 directly.9,10 Incorpora-
tion of this transformation in the synthetic sequence obviates the
previously utilized azide chemistry and the necessary oxidation
state change, while reducing the synthetic sequence to only four
linear steps.
Our exploration of the SAR surrounding UCI lead compounds
1–3 in the insulin secretion assay focused on insulin secretion at
5 mM glucose (high glucose). The ability of each compound to
stimulate basal insulin secretion was also examined, and no com-
pound exhibited signiﬁcant insulinotropic activity at concentra-
tions up to 30 lM in the presence of low glucose (data not
shown). We ﬁrst examined the structure activity relationship of
the C3-substituent using the cyclocondensation of N-amidinyli-
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Scheme 2. Abbreviated route to bicyclic guanidines utilizing Mitsunobu incorporation of the guanidine unit.
Table 2
Insulin secretion SAR of 3-susbstituted hexahydropyrrolo[1,2-c]pyrimidin-1-aminesa
Entry Compound R EC50 (lM) SEM (lM) n % Stimulation SEM (%)
1 2 C6H5 1.25 0.69 4 34 5
2 C3-epi-2 C6H5 2.74 0.57 4 21 4
3 9a H >33 — 5 — —
4 9b C6H11 0.75 0.16 5 40 4
5 9cb 3-Me-C6H4 1.10 0.56 4 20 5
6 9d 3-Br-C6H4 1.01 0.55 4 22 4
7 9e 4-Br-C6H4 0.63 0.06 5 23 6
8 9f 4-F-C6H4 4.04 1.46 5 26 5
9 9gc 4-Me-C6H4 1.00 0.22 4 40 8
10 9h 2-Me-C6H4 1.01 0.18 4 59 10
11 9ib 2-Br-C6H4 0.67 0.09 4 52 7
12 9j 4-CF3-C6H4 >33 — 5 — —
13 9k 4-CO2H-C6H4 >33 — 4 — —
14 9l 4-N-Ac-C6H4 >33 — 4 — —
15 9mb 3-OMe-C6H4 0.76 0.18 9 21 3
a Compounds were tested for insulin secretagogue activity at 5 mM glucose in INS1-E cells (as described in footnote 4). Data were ﬁt to pharmacological models and mean
and error values for potency and efﬁcacy (% stimulation) were calculated.
b This sample contained up to 10% of the minor epimer based on analysis of the 1H NMR spectrum.
c This sample contained ca 30% of the minor epimer based on analysis of the 1H NMR spectrum.
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prepare 9a–9m (Table 2).11,12 A substituent is necessary at this po-
sition, as evidenced by the lack of activity of the de-phenyl analog
9a.13 The phenyl epimer, C3 epi-2, was not signiﬁcantly less potent
than 2 itself. The cyclopentyl analog 9b retained activity, suggest-
ing that lipophilicity, but not necessarily aromaticity, was required
in this portion of the scaffold, as also indicated by the activity of 1.
Introduction of methyl or bromo substituents in the aryl ring did
not signiﬁcantly impact activity, regardless of their position on
the ring (entries 5–7 and 9–11). However, the nature of the para
substituent proved important. Whereas bromo and methyl were
tolerated, analog 9f bearing the triﬂuoromethyl group proved inac-
tive over the concentration range studied (entry 12).14 Further-
more, incorporation of a para carboxylic acid or an N-acylamino
substituent also resulted in inactive compounds (entries 13 and
14).15
The SAR of the C7 substituent (phenethyl in 2) was explored
next, using the cyclocondensation of styrene with the appropriate
N-amidinyliminium ion precursors to obtain 10a–10m (Table 3).16Deletion of the side chain resulted in a loss of activity over the con-
centration range tested (entry 2). The length and nature of the
space between a phenyl group and the core had a large impact
on activity. Removal of the spacer eliminated activity (entry 3).
The analog with a methylene spacer was perhaps slightly less po-
tent than 2 (entry 4), whereas the analog with a propylene spacer
retained activity (entry 5). Replacement of the ethylene spacer
with biphenyl abrogated activity (entry 6), as did replacement of
phenethyl with an oxymethylene spacer (entry 7). Replacement
of the phenethyl group with n-propyl resulted in decreased activity
(entry 8). Introduction of a 3-bromo substituent on the phenyl ring
afforded a modest increase in potency (entry 9). Of note, incorpo-
ration of a methanesulfonamide at either the 3- or 4-position of the
phenyl substituent resulted in a loss of activity, whereas the meth-
anesulfonamide appended in the 2-position was tolerated (entries
10–12). Finally, the two heteroaryls studied, 4-pyridyl and N-
methylpyrazole, proved inactive (entries 13 and 14).
We next examined the effect of the nature and presence of the
guanidine moiety on insulin secretion (Table 4). Methylation of
Table 4
Insulin secretion SAR of analogs bearing modiﬁcation at the guanidine functionality of 2a
Entry Compound Structure EC50 (lM) SEM (lM) n % Stimulation SEM (%)
1 11a 0.67 0.08 4 29 4
2 11bb 0.60 0.15 4 26 3
3 11c >33 — 5 — —
4 11d >33 — 5 — —
a Compounds were tested for insulin secretagogue activity at 5 mM glucose in INS1-E cells (as described in footnote 4). Data were ﬁt to pharmacological models and mean
and error values for potency and efﬁcacy (% stimulation) were calculated.
b This sample contained ca. 30% of 11a based on analysis of the 1H NMR spectrum.
Table 3
Insulin secretion SAR of the C7 substituenta
Entry Compound R y EC50 (lM) SEM (lM) n % Stimulation SEM (%)
1 2 C6H5 2 1.25 0.69 4 34 5
2 10ab H 0 >33 — 12 — —
3 10b C6H5 0 >33 — 5 — —
4 10c C6H5 1 4.74 1.30 4 52 11
5 10db C6H5 3 0.83 0.28 6 31 7
6 10e 4-Ph-C6H4 0 >33 — 4 — —
7 10f 1 >33 — 7 — —
8 10g CH3 2 11.1 2.5 4 55 10
9 10h 3-Br-C6H4 2 0.45 0.16 4 26 10
10 10i 4-N-Ms-C6H4 2 >33 — 6 — —
11 10j 3-N-Ms-C6H4 2 >33 — 6 — —
12 10k 2-N-Ms-C6H4 2 1.37 3.31 4 54 10
13 10l 4-Pyr 2 >33 — 10 — —
14 10m 2 >33 — 4 — —
a Compounds were tested for insulin secretagogue activity at 5 mM glucose in INS1-E cells (as described in footnote 4). Data were ﬁt to pharmacological models and mean
and error values for potency and efﬁcacy (% stimulation) were calculated.
b This sample contained up to 20% of the minor epimer based on analysis of the 1H NMR spectrum.
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(entries 1 and 2),17 whereas the tert-butoxycarbonyl derivative
11c showed no measurable activity (entry 3).18 Replacement of
the exocyclic guanidine nitrogen with oxygen to afford the
corresponding urea19 also resulted in a loss of activity (entry 4).
Collectively, these data support the necessity of a guanidinium cat-
ion in order to stimulate insulin secretion.Finally we examined compounds 12a–e, containing only one
of the two rings of guanidinium lead structure 2 (Table 5).20
Removing the pyrrolidine ring afforded 12a, which, although less
potent than 2, retained measurable activity (entry 1). Analog 12b,
in which the hexahydropyrrolopyrimidine ring has been opened,
also retained activity (entry 2). That these simple analogs stimu-
lated insulin secretion led us to determine the activity of other
Table 5
Insulin secretion SAR of ring-opened guanidinium saltsa
Entry Compound Structure EC50 (lM) SEM (lM) n % Stimulation SEM (%)
1 12a 4.79 2.44 4 39 15
2 12b 2.47 0.79 6 84 13
3 7 1.33 0.36 6 62 7
4 12cb 5.03 1.35 5 54 12
5 12dc 4.87 2.99 4 29 8
6 12ed 5.74 3.66 4 56 9
a Compounds were tested for insulin secretagogue activity at 5 mM glucose in INS1-E cells (as described in footnote 4). Data were ﬁt to pharmacological models and mean
and error values for potency and efﬁcacy (% stimulation) were calculated.
b This sample contained a 1:1 mixture of diastereomers based upon 1H NMR analysis.
c This sample contained a ca. 3:1 mixture of epimers based on analysis of the 1H NMR spectrum. The major isomer was assumed to be syn, in line with the published data
(Ref. 20).
d This sample contained a ca. 9:1 syn/anti mixture based on 1H NMR NOE experiments.
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Figure 1. Stimulation of insulin secretion with compound 9h in isolated rat
pancreatic islets at 3 and 11 mM glucose. Insulin secretion was measured in the
presence of vehicle (white bars) or 3 lM compound 9h (black bars). ⁄P < 0.05 versus
insulin secretion in the vehicle group at 11 mM glucose.
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proved equipotent to 2 (entry 3). Of note in this series, compound
12c bearing a phenyl substituent adjacent to the pyrrolidine
nitrogen provided single-digit micromolar activity (entry 4). This
result contrasts with the lack of activity observed for the
corresponding phenyl analogue in the bicylic guanidinium series
(Table 3, entry 2). Of further note, replacement of the thioether
of 7 with either a phenethyl or benzyl group resulted in a modest
loss in potency (Table 5, entries 5 and 6). Overall, these data
demonstrate how critical the presence of the guanidine group is
for activity in this series of insulin secretogogues.
To determine whether the 3-arylhexahydropyrrolo[1,2-c]pyr-
imidin-1-amines stimulate insulin secretion in a glucose-depen-
dent manner in primary cells, isolated rat pancreatic islets were
treated with different concentrations of compound 9h (Fig. 1).
Secretogogue 9h (3 lM) ampliﬁed glucose-induced insulin secre-
tion at glucose concentrations of 11 mM, but did not increase basal
insulin secretion when the glucose concentration was 3 mM, con-
ﬁrming a glucose-dependent mode of action for this compound.
In summary, using a phenotypic assay, we were able to identify
a class of novel bicyclic guanidines that act as glucose-dependent
insulin secretogogues in both an insulinoma cell line and primary
rat pancreatic b cells. Exploration of the structure–activity
relationship around the scaffold demonstrated the key role of the
guanidine moiety, as well as the importance of two lipophilic
regions. Unfortunately, the exploration did not result in signiﬁcant
increases in potency versus the initial hits, although it is clear that
certain functional groups are not tolerated. The identiﬁcation of
adequate dynamic range in structure–activity relationshipsremains a key attribute for the progression of phenotypic screen-
ing-derived chemotypes into lead optimization campaigns.
The presence of clear structure–activity relationships in the
series studied, as well as the glucose dependency of the effects,
suggest that the compounds elicit a secretory response from cells
by a discrete interaction with a molecular target or set of related
targets, rather than through ill-deﬁned or cytotoxic cell modiﬁca-
tions. The necessity of the guanidine group for activity suggests
that this scaffold might share a mode of action with other guani-
dines21 or even imidazolines that are known to be insulinotropic
agents.22 Even though the glucose-lowering effects of some of
these agents have been demonstrated clinically,23–25 their molecu-
lar targets remain undiscovered despite intensive investigation.
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